BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Polymedco Introduces Point of Care Test for Recurrent Bladder Cancer Detection


1/29/2009 12:08:56 PM

BTA stat(R) Test Detects Bladder Tumor Associated Antigen in Urine

CORTLANDT MANOR, N.Y., Jan. 29 /PRNewswire/ -- Polymedco, Inc. is pleased to announce the direct availability of the BTA stat(R) test from our sales force -- The BTA stat(R) test is a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor associated antigen in urine. It is a single-step, rapid immunochromatographic assay for bladder tumor-associated antigen in voided urine. The specificity of the BTA stat(R) test was 93 - 95% in patients with non-genitourinary diseases and cancers and healthy individuals tested as part of a multi-center study. The test has a sensitivity that is considerably higher than voided urine cytology, enabling detection of recurrent early stage and grade cancers that cytology often misses. Requiring three drops of urine, the result is delivered in only five minutes. The appearance of a line in the patient window indicates a positive result. The BTA stat(R) test requires one voided urine sample with no sample preparation. The BTA stat(R) test is CLIA waived and also available for prescription home use.

Bladder cancer is the fourth most common cancer among men. Over 14,000 deaths are expected this year and 68,810 new cases will be diagnosed with the disease. It has a 5-year survival rate of 94% if caught early and recurs in over 88% of patients within fifteen years, calling for regular testing and lifelong management.

Polymedco, Inc. is one of the leading marketing and distribution companies in the clinical laboratory marketplace. Since the company's inception in 1980, Polymedco has evolved into a highly skilled and successful sales, marketing and manufacturing organization.

For More Information, please contact Polymedco at 800-431-2123 or 914-739-5400, or visit our website: http://www.polymedco.com; www.btastat.com

CONTACT: Helen Landicho, Polymedco, Inc., +1-206-262-7363,
hlandicho@polymedco.com

Web site: http://www.polymedco.com/



Read at BioSpace.com

Polymedco
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES